Aviva PLC Exelixis, Inc. Transaction History

Aviva PLC

$36.8 Billion
Q3 2024

A detailed history of Aviva PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Aviva PLC holds 24,927 shares of EXEL stock, worth $834,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,927

Holding current value

$834,555

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $547,396 - $687,985	24,927 New	24,927 $646,000
Q2 2021 Aug 10, 2021	SELL	$17.95 - $25.56 $977,574 - $1.39 Million	-54,461 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$20.53 - $25.22 $108,439 - $133,212	5,282 Added 10.74%	54,461 $1.23 Million
Q4 2020 Feb 10, 2021	SELL	$18.39 - $24.8 $733,172 - $988,726	-39,868 Reduced 44.77%	49,179 $987,000
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $236,278 - $307,951	-11,431 Reduced 11.38%	89,047 $2.18 Million
Q2 2020 Aug 13, 2020	SELL	$16.46 - $27.42 $1.82 Million - $3.03 Million	-110,340 Reduced 52.34%	100,478 $2.39 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $1.39 Million - $2.1 Million	96,109 Added 83.79%	210,818 $3.63 Million
Q4 2019 Feb 10, 2020	BUY	$15.15 - $18.89 $1.74 Million - $2.17 Million	114,709 New	114,709 $2.02 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

Black Rock Inc. New York, NY

33.5M
Shares

$1.12 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.3M
Shares

$981 Million
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

25.4M
Shares

$851 Million
3.31% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.4M
Shares

$514 Million
0.63% of portfolio
State Street Corp Boston, MA

11.4M
Shares

$383 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account